Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000991656 | SCV001143302 | benign | not provided | 2022-07-21 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000991656 | SCV001813707 | uncertain significance | not provided | 2024-01-10 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect |
Labcorp Genetics |
RCV000991656 | SCV002365831 | likely benign | not provided | 2024-01-14 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV002279684 | SCV002566436 | uncertain significance | Connective tissue disorder | 2019-12-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004030127 | SCV004929801 | uncertain significance | Inborn genetic diseases | 2024-01-25 | criteria provided, single submitter | clinical testing | The c.245C>T (p.P82L) alteration is located in exon 4 (coding exon 4) of the COL9A3 gene. This alteration results from a C to T substitution at nucleotide position 245, causing the proline (P) at amino acid position 82 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |